Advertisement

PharmacoEconomics

, Volume 6, Issue 4, pp 358–369 | Cite as

Economic Outcomes of Colfosceril Palmitate Rescue Therapy in Infants Weighing 1250g or More with Respiratory Distress Syndrome

Results from a Randomised Trial
  • Martin E. Backhouse
  • Josephine A. Mauskopf
  • David Jones
  • Diane E. Wold
  • Robert Schumacher
  • Robert Cotton
  • Walker A. Long
Original Research Article Resource Use with Synthetic Surfactant

Abstract

Summary

An analysis of the economic data from a l11ulticClltrc, randomised, placebocontrolled clinical trial of colfosccri l palmitate in infants with neonatal respiratory distress syndrome (NRDS) and birthweights of I 250g or more is presented.

Two 5 ml/kg (67.5 mglkg) doses of a synthetic surfactant (co!fosceri! palmitate) or air placebo were administered to 1237 infants who were receiving mechanical ventilation and had an arterial/alveolar oxygen tension ratio of less than 0.22. In addition to the clinical end-points for safety and efficacy. data were collected on length of hospital stay. days in the neonatal intensive care unit, days on mechanical ventilation. days on oxygen. and hospital charges until the child reached 1-year adjusted age. One-year adjusted age is attained when the time elapsed since binh is equal to 365 days plus the number of days of prematurity.

Rescue treatment with synthetic surfactant therapy has been shown to reduce the incidence of complications ofNRDS. Growth and development of infants who received colfosceril palmitate therapy in the study and survived to 1-year adjusted age were equivalent to those of the survivors in the air placebo group. For the cohort of treated infants, colfosceril palmitate reduced the avemge length of stay at 2 levels of care needed during both the initial hospitalisation (it reduction of 8 days overall and 5 days in intensive care) and all first year hospitalisations (a reduction of 9 days overall and 5 days in intensive care). Total hospital charges for the initial hospitalisation and through I-year adjusted age for a hypothetical cohort of 100 infants treated with colfosceril palmitate were less than those for a comparable cohon in the air placebo group.

The results wou ld, therefore, suggest that rescue therapy with colfosceril palmitate in infants with NRDS and binhweighlsover [250g can result in substantial reductions in hospital resource utilisation and charges in addition to the clinical benefits associated with its use.

Keywords

Palmitate Neonalal Intensive Care Unit Hospital Charge Initial Hospitalisation Synthetic Surfactant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Long W, Thompson T, Sundell H, et al. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. J Pediatr 1991; 118: 595–605PubMedCrossRefGoogle Scholar
  2. 2.
    Long W, Cofbet A, Cotton R, et al. A controlled trial of synthetic surfactant in infants weighing 1,250 grams or more with respirutory distress syndrome. N Engl J Med 1991; 325: 1696–703PubMedCrossRefGoogle Scholar
  3. 3.
    The Osiris Collaborative Group. Early versus delayed neonatal administrdtion of a synthetic surfactant — the judgement of OSIRIS. Lancet 1992; 340: 1363-9Google Scholar
  4. 4.
    Combet A, Bucciarelli R, Gotdlrnln S, et al. Decreased monality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pcdiatr 1991; 118: 277–84Google Scholar
  5. 5.
    Kitzhabcr J. The Oregon Health Plan. Salem: Oregon State Scnate. 1992Google Scholar
  6. 6.
    Onturio Ministry of Health. Guidelines for preparation of economic analyses tObe included in submision to drug programs branch for listing in the Ontario Drug Benefit Formulary/Comparative Drug Index. Toronto: Ministry of Health, 1991Google Scholar
  7. 7.
    Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. PharmacoEconomics 1993; 3: 354–61PubMedCrossRefGoogle Scholar
  8. 8.
    Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee, including submissions involving economic analyses. Canberra: Department of Health, Housing, and Community Services, 1992Google Scholar
  9. 9.
    Drummond M, Smith GT, Wells N. Economic evaluation in the development of medicines. London: Office of Health Economics, 1988Google Scholar
  10. 10.
    Backhouse M, Backhause R, Edey S. Economic evaluation bibliography. Health Econ 1992; 1 Suppl.: 1–236Google Scholar
  11. 11.
    Pancth N, Kiely JL, Wallenstein S, et al. Newborn intensive care and neonatal mortality in low-birth weight in fants: a population study. N Engl J Med 1982; 307: 149–55CrossRefGoogle Scholar
  12. 12.
    Phibbs CS, Williams RL, Phibbs RH. Newborn risk factors and costs of neonatal intensive care. Pediatrics 1981; 68: 313–21PubMedGoogle Scholar
  13. 13.
    Boyle MH, Torrance GW, Sinclair JC, et al. Economic evaluation of neonatal intensive eare of very-low-birthweight infants. N Engl J Med 1983; 308: 1330–7PubMedCrossRefGoogle Scholar
  14. 14.
    Showstack JA, Stone MH, Schroeder SA. The role of changing clinical practices in the rising costs of hospital care. N Engl J Med 1985; 313: 1201–7PubMedCrossRefGoogle Scholar
  15. 15.
    Schwanz R, Luby A, Scanlon J, et al. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 grams. N Engl J Med 1994; 330: 1476–80CrossRefGoogle Scholar
  16. 16.
    Mugford M, Howard S. Cost-effectiveness of surfactunt replacement in preterm babies. PharmacoEconomics 1993; 3: 362–73PubMedCrossRefGoogle Scholar
  17. 17.
    Merrill TA, Hallman M, Vaucher Y, et al. Impact of surfactant treatment on cost of neonatal intensive care: a cost-benefit analysis. J Perinatol 1991; 10: 416–9Google Scholar
  18. 18.
    Mugford M, Piercy J, Chalmers I, Chalmers I. Cost implications of different approaches to the prevention of respiratory distress syndrome. Arch Dis Child 1991; 68: 757–64CrossRefGoogle Scholar
  19. 19.
    Tubman TRJ, Halliday HL, Normand C. Cost of surfactant replacement teatment for severe neonatal respiratory distress syndrome: a randomised controlled trial. BMJ 1990; 301: 842–5PubMedCrossRefGoogle Scholar
  20. 20.
    Maniscalco WM, Kendig JW, Shapiro DL. Surfactant replacement therapy: impact On hospital charges for premature infants with respiratory distress syndrome. Pediatrics 1989; 83: 1/6/2012Google Scholar
  21. 21.
    Phibbs CS, Phibbs RH, Wakely A, et al. Cost effects of surfactant therapy for neOnatal respiratory distress syndrome. J Pediatr 1993; 123: 953–62PubMedCrossRefGoogle Scholar
  22. 22.
    Sauve R. Developmental outcome at one year of infants treated with Exosurf Neonatal. In: Long W, Tilson H, editors. Proceedings of the Exosurf Neonatal investigatOr’s meeting: 1991 Nov 13-14. Langhorne: Adis International, 1992Google Scholar
  23. 23.
    National Center for Health Statistics. Annual summary of binhs, marriages, divorces and deaths: United States 1992Google Scholar
  24. 24.
    Goldman L, Weinstein MW, Goldman PA, et al. 1992. Costeffectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary hean disease: projection of coronary hean disease model. JAMA 1991; 265: 1145–51PubMedCrossRefGoogle Scholar
  25. 25.
    Resnick MB, Ariet M, Caner RL, et al. Prospective pricing system for leniary neonatal intensive care. Pediatrics 1986; 78: 820–8PubMedGoogle Scholar
  26. 26.
    Finkler S. The distinction between Costs and charges. Ann Intern Mcd 1982; 96: 102–9Google Scholar
  27. 27.
    Yamaguchi K. Event history analysis. Newbury Park CA: Sage Publications, 1991Google Scholar
  28. 28.
    Crystal S, Sambamoonhi U, Merzal C. Estimating the per-case cost of AIDS care. Presented at the APHA Annual Meeting: 1992 Nov 8-12: WashingtonGoogle Scholar
  29. 29.
    Markson L, McKee L, Mauskopf J, et al. Medicaid expenditures for AIDS diagnosis, mid-illness, and death. Presented at the APHA Annual Meeting; 1992 Nov 8-12: WashingtonGoogle Scholar
  30. 30.
    Drummond M, Vella S, Backhouse M, et al. Cost-effectiveness of zidovudine therapy for people wilh AIDS: results from long-term follow-up. Presented at the 7th International AIDS Conference: 1991 Jun 16-21: FlorenceGoogle Scholar
  31. 31.
    Eidelman A. Economic consequences of surfactant therapy. J Pcrinatol 1993; 13: 137–9Google Scholar
  32. 32.
    Grogaard JR, Lindstrom DP, Parker RA, et al. Increased Survival rate in very low birth weight infants (1,500 grams or less): no association with increased risk of handicaps. J Pediatr 1990; 117: 139–46PubMedCrossRefGoogle Scholar
  33. 33.
    Ware J, Tacusch HW, SoH RF, et al. Health and developmental outcomes of a surfactant controlled trials foHow-up at 2 years. Pediatrics 1990; 85: 1103–7PubMedGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Martin E. Backhouse
    • 1
  • Josephine A. Mauskopf
    • 1
  • David Jones
    • 1
  • Diane E. Wold
    • 1
  • Robert Schumacher
    • 2
  • Robert Cotton
    • 3
  • Walker A. Long
    • 4
  1. 1.Burroughs Wellcome CoResearch Triangle ParkUSA
  2. 2.University of Michigan HospitalsAnn ArborUSA
  3. 3.Vanderbilt University Medical CenterNashvilleUSA
  4. 4.University of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations